A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats

• Главные авторы: Teruhiko Mizumoto (Автор), Yutaka Kakizoe (Автор), Terumasa Nakagawa (Автор), Yasunobu Iwata (Автор), Yoshikazu Miyasato (Автор), Kohei Uchimura (Автор), Masataka Adachi (Автор), Qinyuan Deng (Автор), Manabu Hayata (Автор), Jun Morinaga (Автор), Taku Miyoshi (Автор), Yuichiro Izumi (Автор), Takashige Kuwabara (Автор), Yoshiki Sakai (Автор), Kimio Tomita (Автор), Kenichiro Kitamura (Автор), Masashi Mukoyama (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2021-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Metabolic syndrome (MetS) is associated with chronic kidney disease and proteinuria. Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models. The present study evaluated the anti-hypertensive and anti...